Comparison of C-type Nanoantibody Produced in Different Expression Systems Implying Potential Clinical Applications
Molecular Pharmaceutics · 2025
DOI: 10.1021/acs.molpharmaceut.4c00980 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Molecular Pharmaceutics, 2025. Verfasst von Moxuan Li und 6 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Virology and Biosafety, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Sciences, Wuhan, Hubei 4…. Hauptthemen laut MEDLINE: Cricetulus. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 38 Literaturangaben. Gefördert von: Natural Science Foundation of Hubei Province, National Natural Science Foundation of China.
Abstract (Originalsprache)
In the pharmaceutical industry, the Chinese hamster ovary cell, a type of mammalian cell, is extensively employed for the production of conventional full-length monoclonal antibodies. Nanobody is one of the most attractive directions for the development of next-generation antibody drugs. However, a suitable expression system for its manufacture has not yet been comprehensively evaluated. Previously, we proposed that the immunoglobulin constant CH2 domain could be a promising scaffold for developing C-type nanoantibodies (C-Nabs) as candidate therapeutics. Here, we used an antiviral C-Nab, which we identified previously (under review), as a model for investigation. We expressed C-Nabs without a tag in different systems, including a bacterium (C-Nabbac), yeast (C-Nabyeast), and mammalian cell (C-Nabmam). After purification, the binding and neutralizing activities of C-Nabs from different expression systems are similar. Their secondary structures are rich in β-strand. The melting temperatures of C-Nabbac (71.5 °C) and C-Nabmam (70.2 °C) are similar, which are slightly higher than that of C-Nabyeast (65.6 °C), while C-Nabyeast and C-Nabmam are more resistant to urea-induced unfolding than C-Nabbac. C-Nabyeast and C-Nabmam demonstrate higher resistance to aggregation compared to C-Nabbac. C-Nabyeast exhibits greater resistance to enzyme digestion compared to C-Nabbac and C-Nabmam. Notably, when administered via intraperitoneal injection in mice, C-Nabyeast shows superior pharmacokinetics. Overall, after comparing C-Nab proteins from various expression systems, we determined that yeast is the most suitable host for producing C-Nabs. This finding is beneficial for the production of nanobodies as potential drug candidates.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Key Laboratory of Virology and Biosafety, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Sciences, Wuhan, Hubei 430207, China.
- University of Chinese Academy of Sciences, Beijing 100049, China.
- Hubei Jiangxia Laboratory, Wuhan, Hubei 430200, China.
ORCID-Profile: Rui Gong
Förderung
- Natural Science Foundation of Hubei Province
- National Natural Science Foundation of China
Zitieren
APA
Li, M., Zhan, Y., Wu, B., Qin, Y., Gao, J., Liu, L., & Gong, R. (2025). Comparison of C-type Nanoantibody Produced in Different Expression Systems Implying Potential Clinical Applications. Molecular Pharmaceutics. https://doi.org/10.1021/acs.molpharmaceut.4c00980
Vancouver
Li M, Zhan Y, Wu B, Qin Y, Gao J, Liu L, et al. Comparison of C-type Nanoantibody Produced in Different Expression Systems Implying Potential Clinical Applications. Molecular Pharmaceutics. 2025. doi:10.1021/acs.molpharmaceut.4c00980
BibTeX
@article{Li2025,
author = {Li, Moxuan and Zhan, Yancheng and Wu, Bihao and Qin, Ye and Gao, Jiazhao and Liu, Lan and Gong, Rui},
title = {Comparison of C-type Nanoantibody Produced in Different Expression Systems Implying Potential Clinical Applications},
journal = {Molecular Pharmaceutics},
year = {2025},
doi = {10.1021/acs.molpharmaceut.4c00980}
}
EUVIMED